1259933-16-8 Usage
Description
XEN402 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those expressed in the pain-sensing peripheral nervous system. It has potentially broad application in nociceptive pain, including inflammatory pain and neuropathic pain indications.
Uses
Used in Pain Management:
XEN402 is used as a pain management agent for the treatment of inflammatory pain and neuropathic pain. It works by inhibiting the sodium channel Nav1.7 and other sodium channels in the pain-sensing peripheral nervous system, thereby reducing pain signals and providing relief to patients.
Used in Pharmaceutical Industry:
XEN402 is used as a drug candidate in the pharmaceutical industry for the development of novel pain management therapies. Its broad application in nociceptive pain makes it a promising candidate for the treatment of various pain conditions, offering new treatment options for patients suffering from chronic and acute pain.
Check Digit Verification of cas no
The CAS Registry Mumber 1259933-16-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,9,9,3 and 3 respectively; the second part has 2 digits, 1 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1259933-16:
(9*1)+(8*2)+(7*5)+(6*9)+(5*9)+(4*3)+(3*3)+(2*1)+(1*6)=188
188 % 10 = 8
So 1259933-16-8 is a valid CAS Registry Number.
1259933-16-8Relevant articles and documents
ASYMMETRIC SYNTHESIS OF FUNAPIDE
-
, (2018/01/20)
This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
Preparation of chiral 3-aryl-3-hydroxymethyl-2-indolone compounds
-
, (2017/04/21)
The invention relates to a preparation method of chiral 3-aryl-3-hydroxymethyl-2-indolone compounds representing by formula IV and formula V. The reaction process is also disclosed in the invention.
ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS
-
Paragraph 0239; 0240, (2013/10/22)
This invention is directed to asymmetric syntheses of certain spiro-oxindole derivatives, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.